Page 14 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

HBV and HCV eradication and HCC risk

Chien-Wei Su

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General

Hospital;

Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan

Abstract

Hepatocellular carcinoma (HCC) is the sixth most frequent malignancies and the in

the world. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the most common

etiological factors of HCC. Active HBV or HCV replication are the major drivers of

hepatocarcinogenesis in patients with chronic viral hepatitis. Because anti-viral therapy can suppress

viral replication, ameliorate liver inflammation, reduce (or even regress) fibrosis, and improve liver

functional reserve, several lines of evidences confirm that anti-viral therapy could reduce the risk of

HCC development patients for patients with chronic HBV or HCV infection,especially for those

with successful eradication of the virus after therapy. However, antiviral therapy could reduce, but it

could not completely eliminate the risk of HCC, especially for patients with liver cirrhosis or portal

hypertension. Moreover, its role in reducing recurrence rate of HCC after curative therapy is still

controversial. This may be due to differences in demographic characteristics, liver functional reserve,

and tumor factors in previous reports. We will discuss the potential impact of antiviral therapy on the

prevention of HCC occurrence and recurrence after curative therapies.